Business Description
MeiraGTx Holdings plc is a New York-based company founded in 2015 that researches and develops gene therapies for patients with serious conditions affecting vision, the nervous system, and salivary gland function. Its pipeline includes treatments for inherited eye disorders, Parkinson's disease, and dry mouth caused by radiation therapy, with several programs currently in clinical trials. The company also maintains early-stage research into conditions such as Alzheimer's disease, ALS, and age-related macular degeneration. MeiraGTx works alongside Johnson & Johnson Innovative Medicine and Hologen Limited to advance and commercialize select therapies.
